Scopia Surgical Secures $2.65M Pre-Seed for Robotic Surgery Navigation

Scopia Surgical recently closed an oversubscribed pre-seed financing round, securing $2.65M to accelerate its medical technology platform. The Montreal based company builds artificial intelligence software designed to guide doctors during minimally invasive operations. Linearis Ventures and Anges Québec co-led the financial injection. Other participants included Investissement Québec through its Fonds Impulsion program, HaloHealth, and individual investors Richard Rubin and Suresh Madan. This initial capital gives the engineering team the resources needed to push their software into active medical testing.

Guiding Robotic Hands

Operating on soft tissue presents major difficulties for modern surgeons. While hospitals spend heavily to acquire robotic arms and physical operating systems, doctors often lose visual anatomical details once the actual procedure begins. Preoperative scans provide a clear map of the body, but that map becomes hidden during the live operation. Scopia Surgical solves this problem by functioning like a GPS for the surgical suite. The software combines spatial tracking with patient specific digital twins, bringing high fidelity imaging directly into the operating room in real time.

Reducing Errors in the Operating Room

By giving doctors a constant view of internal structures, the software lowers the chances of misidentifying tissue and causing accidental damage during gynecological, urologic, and colorectal procedures. Chief Executive Officer Gabriel Rivest stated that the medical industry has already built the physical arms of robotic systems, and now the sector needs intelligent software to act as the brain. Startups applying machine learning to the medical field continue to attract heavy capital, matching the financial patterns we saw when Scan.com secured $220M in funding to expand its US medical imaging network.

Clinical Validation and Future Approvals

The founders, Rivest and Chief Technology Officer Sébastien Delorme, plan to use the $2.65M to hire additional engineers and clinical staff. Their immediate goal involves launching early clinical evaluations across three major North American hospitals. The software will undergo testing at the CHUM and the Jewish General Hospital in Montreal, along with the Medical University of South Carolina. The data collected from these early tests will support future applications for regulatory clearance, specifically targeting approval as a Class 2 medical product from the United States Food and Drug Administration over the next two years. Building software that integrates safely with hardware takes immense planning, similar to the hardware developments covered when a16z launched a fund for artificial intelligence infrastructure.

Read More on TechRobust:

• Scan.com secures $220M funding for US medical imaging
• AIR secures $50M seed funding to protect enterprise supply chains
• Apple foldable iPhone manufacturing delays hinge durability